ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i1.171ppharm-368Research ArticleДИСКУССИОННЫЕ ВОПРОСЫ ФАРМАКОТЕРАПИИDEBATABLE ISSUES OF PHARMACOTHERAPYОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБА У БОЛЬНОГО ЮВЕНИЛЬНЫМ АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ И УВЕИТОМEXPERIENCE OF ADALIMUMAB TREATMENT IN PATIENT WITH JUVENILE ANKYLOSING SPONDYLITIS AND UVEITISМитенкоЕ. В.MitenkoE. V.neonatepearl@yandex.ruАлексееваЕ. И.AlekseevaE. I.
доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центраздоровья детей РАМН
neonatepearl@yandex.ruБзароваТ. М.BzarovaT. M.neonatepearl@yandex.ruВалиеваС. И.ValievaS. I.neonatepearl@yandex.ruЧомахидзеА. М.TchomachidzeA. M.neonatepearl@yandex.ruИсаеваК. Б.IsaevaK. B.neonatepearl@yandex.ruЧистяковаЕ. Г.TchistyakovaE. G.neonatepearl@yandex.ruДенисоваР. В.DenisovaR. V.neonatepearl@yandex.ruСлепцоваТ. В.SleptsovaT. V.neonatepearl@yandex.ruПоляеваТ. Ю.PolyaevaT. J.neonatepearl@yandex.ruФетисоваА. Н.FetisovaA. N.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children’s Health RAMS, MoscowRussian Federation20121901201291Педиатрическая фармакология118124Copyright © Митенко Е.В., Алексеева Е.И., Бзарова Т.М., Валиева С.И., Чомахидзе А.М., Исаева К.Б., Чистякова Е.Г., Денисова Р.В., Слепцова Т.В., Поляева Т.Ю., Фетисова А.Н., 20122012Митенко Е.В., Алексеева Е.И., Бзарова Т.М., Валиева С.И., Чомахидзе А.М., Исаева К.Б., Чистякова Е.Г., Денисова Р.В., Слепцова Т.В., Поляева Т.Ю., Фетисова А.Н.Mitenko E.V., Alekseeva E.I., Bzarova T.M., Valieva S.I., Tchomachidze A.M., Isaeva K.B., Tchistyakova E.G., Denisova R.V., Sleptsova T.V., Polyaeva T.J., Fetisova A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/368детиювенильный идиопатический артритювенильный анкилозирующий спондилитувеитадалимумабchildrenankylosingspondylitisuveitisadalimumabReferencesCassidy J., Petty R. eds. 6th еd. Texbook of paediatric rheumatology. Elsevier Saunders. 2010.Cassidy J., Petty R. eds. 6th еd. Texbook of paediatric rheumatology. Elsevier Saunders. 2010.Benеzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89 (4): 444–48.Benеzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89 (4): 444–48.Foster C. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current. Opin. Ophthalmol. 2003; 14 (6): 395–98.Foster C. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current. Opin. Ophthalmol. 2003; 14 (6): 395–98.Dana M., Merayo Lloves J., Schaumberg D., Foster C. S. Visual outcomes prognosticators in juvenile rheumatoid arthritis associated uveitis. Ophthalmology. 1997; 104 (2): 236–44.Dana M., Merayo Lloves J., Schaumberg D., Foster C. S. Visual outcomes prognosticators in juvenile rheumatoid arthritis associated uveitis. Ophthalmology. 1997; 104 (2): 236–44.Bombardieri S., Ruiz A., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007. doi:10.1093/rheumatology/kem091.Bombardieri S., Ruiz A., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology. 2007. doi:10.1093/rheumatology/kem091.Burmester G. et al., Three-Year Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis with and without History of Other Tumor Necrosis Factor Antagonist Therapies. ACR. 2009, abstract 1681.Burmester G. et al., Three-Year Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis with and without History of Other Tumor Necrosis Factor Antagonist Therapies. ACR. 2009, abstract 1681.Wick M.C. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005; 34: 353–8.Wick M.C. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005; 34: 353–8.Rudwaleit M., Van den Bosch F., Kron M. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010; 12 (3): R117.Rudwaleit M., Van den Bosch F., Kron M. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010; 12 (3): R117.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint Bone Spine. 2004; 71: 601–3.Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint Bone Spine. 2004; 71: 601–3.Van der Heijde D., Salonen D., Weissman B. N., Landewe R. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 2009; 11 (4): 127.Van der Heijde D., Salonen D., Weissman B. N., Landewe R. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 2009; 11 (4): 127.Van der Heijde D. et al. Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheum. 2006 Jul; 54(7): 2136–46.Van der Heijde D. et al. Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheum. 2006 Jul; 54(7): 2136–46.Van der Heijde et al. Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results. ACR11 — Arthritis & Rheumatism. 2011; 63(10) abstract 535.Van der Heijde et al. Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results. ACR11 — Arthritis & Rheumatism. 2011; 63(10) abstract 535.Rudwaleit M., Claudepierre P. J. et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rheumatol. 2009; 36 (4): 801–808.Rudwaleit M., Claudepierre P. J. et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rheumatol. 2009; 36 (4): 801–808.Rudwaleit M., Claudepierre P., Kron M. et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 2010; 12 (2): 43.Rudwaleit M., Claudepierre P., Kron M. et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 2010; 12 (2): 43.Алексеева Е. И., Алексеева А. М., Бзарова Т. М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20.Алексеева Е. И., Алексеева А. М., Бзарова Т. М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20.Barrera P., Boerbooms A. M., Janssen E. M. et al. Circulating soluble tumor necrosis factor receptors, interleukin 2 receptors, tumor necrosis factor alpha, and interleukin 6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36 (8): 1070–1079.Barrera P., Boerbooms A. M., Janssen E. M. et al. Circulating soluble tumor necrosis factor receptors, interleukin 2 receptors, tumor necrosis factor alpha, and interleukin 6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36 (8): 1070–1079.Kalden J. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Research. 2002; 4 (Suppl. 2): 34–40.Kalden J. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Research. 2002; 4 (Suppl. 2): 34–40.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Annals of Rheumatic Disease. 2003; 62 (3): 245–47.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Annals of Rheumatic Disease. 2003; 62 (3): 245–47.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of juvenile idiopathic arthritis associated uveitis — a pilot study. 8th Annual European League Against Rheumatism. Barcelona. 2007. Abstract THU0483. 20. Vazquez Cobian L. B., Flynn T., Lehman T. J. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149 (4): 572–75.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of juvenile idiopathic arthritis associated uveitis — a pilot study. 8th Annual European League Against Rheumatism. Barcelona. 2007. Abstract THU0483. 20. Vazquez Cobian L. B., Flynn T., Lehman T. J. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149 (4): 572–75.Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd. 2007; 224 (6): 526–31.Heiligenhaus A., Horneff G., Greiner K. et al. Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd. 2007; 224 (6): 526–31.SIMONINI G., TADDIO A., CATTALINI M. et al. Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-Label Comparative Study of Adalimumab Versus Infliximab. Arthritis Care & Research. 2011; 63 (4): 612–618.SIMONINI G., TADDIO A., CATTALINI M. et al. Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-Label Comparative Study of Adalimumab Versus Infliximab. Arthritis Care & Research. 2011; 63 (4): 612–618.
The authors declare that there are no conflicts of interest present.